Skip to the page

Data / Drug companies / P & L Development, LLC

P & L Development, LLC: 81 products in the FDA NDC directory, labeler code 59726

P & L Development, LLC (labeler code 59726) lists 81 products in the FDA National Drug Code Directory, covering 23 finished drugs by generic name. By type: 68 over the counter drugs, 13 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 15, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
59726
Products in commercial distribution
81
Packages
135
Finished drugs by generic name
23
Prescription products
0
Over the counter products
68
Flagged as original packager
64 of 64 products that carry the flag
Started marketing in the last 12 months
6
Products with a marketing end date set
19
Earliest marketing start
March 31, 2016
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)4353.1%
Over the counter monograph drugs2530.9%
Bulk ingredients for compounding1316%

Products by type

TypeProductsShare
Over the counter drugs6884%
Bulk ingredients1316%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Capsule, liquid filled1822.2%
Gum, chewing1721%
Tablet, coated89.9%
Tablet67.4%
Cream67.4%
Capsule67.4%
Aerosol, foam56.2%
Lozenge44.9%
Tablet, delayed release33.7%
Tablet, extended release22.5%
Gel22.5%
Spray, metered22.5%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Fluticasone Propionate59726-350Spray, meteredGeneric drugs (ANDA)August 15, 2026
Aspirin59726-103Tablet, coatedOver the counter monograph drugsAugust 15, 2026
Ibuprofen59726-003Tablet, coatedGeneric drugs (ANDA)August 15, 2026
Pain Reliever59726-113Chewable gelOver the counter monograph drugsJune 30, 2026
Headache Relief Extra Strength59726-586Tablet, coatedOver the counter monograph drugsJune 20, 2026
Allergy Relief59726-203Spray, meteredGeneric drugs (ANDA)May 15, 2026
Omeprazole59726-744Tablet, delayed releaseGeneric drugs (ANDA)August 29, 2025
Omeprazole59726-740Tablet, delayed releaseGeneric drugs (ANDA)August 15, 2025
Nicotine Mini59726-652LozengeGeneric drugs (ANDA)June 1, 2025
Nicotine59726-650LozengeGeneric drugs (ANDA)June 1, 2025
Mucus Relief59726-237Tablet, extended releaseGeneric drugs (ANDA)February 15, 2025
Omeprazole59726-298Tablet, delayed releaseGeneric drugs (ANDA)January 31, 2025
Cold Sore Fever Blister59726-221CreamGeneric drugs (ANDA)January 31, 2025
Mucus Relief59726-734Tablet, extended releaseGeneric drugs (ANDA)December 6, 2024
Ibuprofen59726-279Capsule, liquid filledGeneric drugs (ANDA)December 1, 2024
Nicotine polacrilex59726-428Gum, chewingBulk ingredients for compoundingNovember 30, 2024
Nicotine polacrilex59726-613Gum, chewingBulk ingredients for compoundingOctober 22, 2024
Nicotine polacrilex59726-612Gum, chewingBulk ingredients for compoundingOctober 22, 2024
Nicotine polacrilex59726-609Gum, chewingBulk ingredients for compoundingOctober 22, 2024
Nicotine polacrilex59726-608Gum, chewingBulk ingredients for compoundingOctober 22, 2024
Nicotine polacrilex59726-605Gum, chewingBulk ingredients for compoundingOctober 22, 2024
Nicotine polacrilex59726-503Gum, chewingBulk ingredients for compoundingOctober 22, 2024
Nicotine polacrilex59726-499Gum, chewingBulk ingredients for compoundingOctober 22, 2024
Nicotine polacrilex59726-496Gum, chewingBulk ingredients for compoundingOctober 22, 2024
Nicotine polacrilex59726-482Gum, chewingBulk ingredients for compoundingOctober 22, 2024

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.